Skip to Content
Merck
  • Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis.

Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis.

Biomicrofluidics (2014-01-10)
Sangjo Shim, Katherine Stemke-Hale, Apostolia M Tsimberidou, Jamileh Noshari, Thomas E Anderson, Peter R C Gascoyne
ABSTRACT

Circulating tumor cells (CTCs) are prognostic markers for the recurrence of cancer and may carry molecular information relevant to cancer diagnosis. Dielectrophoresis (DEP) has been proposed as a molecular marker-independent approach for isolating CTCs from blood and has been shown to be broadly applicable to different types of cancers. However, existing batch-mode microfluidic DEP methods have been unable to process 10 ml clinical blood specimens rapidly enough. To achieve the required processing rates of 10(6) nucleated cells/min, we describe a continuous flow microfluidic processing chamber into which the peripheral blood mononuclear cell fraction of a clinical specimen is slowly injected, deionized by diffusion, and then subjected to a balance of DEP, sedimentation and hydrodynamic lift forces. These forces cause tumor cells to be transported close to the floor of the chamber, while blood cells are carried about three cell diameters above them. The tumor cells are isolated by skimming them from the bottom of the chamber while the blood cells flow to waste. The principles, design, and modeling of the continuous-flow system are presented. To illustrate operation of the technology, we demonstrate the isolation of circulating colon tumor cells from clinical specimens and verify the tumor origin of these cells by molecular analysis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Catalase from bovine liver, aqueous suspension, 10,000-40,000 units/mg protein